EGFR and non-small cell lung carcinoma: Despite the high response rates to various first and second generation EGFR-TKIs, eventually all patients with advanced NSCLC carrying an EGFR mutation, will progress due to acquired resistance [8, 9], most often due to the EGFR p.(Thr790Met) mutation [10–13].